Bendamustine treatment before apheresis is known to reduce survival in large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T-cell therapy. Bendamustine has been shown to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback